1. International Germ Cell Consensus Classification: A Prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers . J Clin Oncol 1997;15:594–603
2. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized Trial of Etoposide and Cisplatin versus Etoposide and Carboplatin in Patients With Good-Risk Germ Cell Tumors: A Multiinstitutional Study. J Clin Oncol 1993;11:598–606
3. Culine, S., et al., Are 3 Cycles of Cleomycin, Etoposide and Cisplatin (3BEP) or 4 Cycles of Etoposide and Cisplatin (4EP) Equivalent Regimens for Patients with Good-Risk Metastatic Non Seminomatous Germ Cell Tumors (NSGCT)? Preliminary Results of a Randomized Trial. America Society of Clinical Oncology, 1999
4. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin, etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group and Cancer and Leukemia Group B study. J Clin Oncol 1998;16:1287–1293
5. Fox EP, Weathers TD, Williams SD et al. Outcome Analysis for Patients with Persistent Germ Cell Carcinoma in Post Chemotherapy Retroperitoneal Lymph Node Dissections. J Clin Oncol 1993;11: 1294–1299